Collegium Pharmaceutical Inc (COLL)vsUnited Therapeutics Corporation (UTHR)
COLL
Collegium Pharmaceutical Inc
$23.04
+1.19%
HEALTHCARE · Cap: $724.14M
UTHR
United Therapeutics Corporation
$493.10
-0.31%
HEALTHCARE · Cap: $21.22B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 290% more annual revenue ($3.15B vs $808.21M). UTHR leads profitability with a 41.6% profit margin vs 5.9%. UTHR trades at a lower P/E of 17.7x. UTHR earns a higher WallStSmart Score of 61/100 (C+).
COLL
Hold48
out of 100
Grade: D+
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.5%
Fair Value
$391.37
Current Price
$23.04
$368.33 discount
Margin of Safety
+0.8%
Fair Value
$479.67
Current Price
$493.10
$13.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
5.9% margin — thin
Earnings declined 46.6%
Distress zone — elevated risk
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Price/Book.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : COLL
The primary concerns for COLL are Market Cap, Profit Margin, EPS Growth. Debt-to-equity of 2.75 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
COLL profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
COLL carries more volatility with a beta of 0.72 — expect wider price swings.
COLL is growing revenue faster at 6.3% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 48/100), backed by strong 41.6% margins. COLL offers better value entry with a 88.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?